title: Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis.
abstract: OBJECTIVE
  To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.
  
  
  METHODS
  Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.
  
  
  RESULTS
  Six months after beginning the new therapy, it was well-tolerated and the patient's RA and scleritis were quiescent.
  
  
  CONCLUSIONS
  Certolizumab pegol may successfully treat RA-associated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.
authors.affiliation: Department of Ophthalmology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA.
authors.forename: Paul S
authors.initials: PS
authors.lastname: Tlucek
authors.forename: Donald U
authors.initials: DU
authors.lastname: Stone
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D015423:Scleritis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D007155:Immunologic Factors; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol